Celldex Therapeutics

NAS:CLDX

Biotechnology

Market Cap

$46.90mm

SMALL cap

Share Price ↓

$3.61 (-4.24%)

YTD Return ↑

0.2926%

since start of 2019

P/E Ratio

—

CLDX chart by TradingView

Source: FactSet financial data and analytics.

Corporate Values

Carbon Footprint
Pollution Prevention
Water Conservation
Data Privacy
Consumer Health
Employee Satisfaction
Workplace Safety
Corp Gov
Ethical Practices
Conflict Materials
Forced Labor
Gender Diversity

Legend

About

Biotechnology Founded 1983

Celldex Therapeutics, Inc. engages in the research, development, and manufacture of biopharmaceutical products. Its portfolio includes therapeutic antibodies, antibody drug conjugates, vaccines, and immune system modulators. The company's drug candidates include Glembatumumab vedotin, Varlilumab, CDX-1401, CDX-301, and Rintega. Celldex Therapeutics was founded by Anthony S. Marucci and Tibor Keler in 1983 and is headquartered in Hampton, NJ.

website

Source: FactSet Research Systems

Headquarters

Perryville III Building

53 Frontage Road

Suite 220

Hampton, NJ 08827

1.908.454.7120

Executives

Name	Title	Gender
Thomas Andrew Davis, MD	Chief Medical Officer & Executive Vice President	Male
Avery W. Catlin, MBA, CPA	CFO, Secretary, Treasurer & Senior Vice President	Male
Larry Ellberger	Chairman	Male
Anthony S. Marucci, MBA	President, Chief Executive Officer & Director	Male
Tibor Keler, PhD	Chief Scientific Officer & Executive VP	Male
Sarah Boylan Cavanaugh	VP-Investor Relations & Corporate Communications	Female
Theresa M. LaVallee, PhD	Senior VP-Regulatory & Precision Medicine	Female

Mindful Investing Summary

Legend

Carbon Footprint — N/A

Celldex Therapeutics among its competitors for its carbon footprint. A company’s performance in this category is based on its success in implementing energy efficiency measures. Investments in energy efficient technology, green building and sourcing of renewable energy can all lead to cost savings and reduce the company’s contribution to climate change.
Pollution Prevention — N/A

Celldex Therapeutics on this issue. Companies are evaluated on pollution prevention by the levels of waste (including hazardous waste) they produce and release into the environment, and can be affected by whether they develop products that can reduce exposure to pollution.
Water Conservation — N/A

Celldex Therapeutics among its peers in this category. A company’s score in this category depends on its measures to minimize water usage and impacts on stressed or drought-prone water resources.
Data & Privacy Protection — N/A

Celldex Therapeutics among its peers and competitors for data privacy and protection. Companies today digitally manage vast amounts of personal information about their clients. A company’s score on this issue is based on the systems, products and procedures it has in place to minimize the risk for data and privacy breaches.
Consumer Health, Wellness & Safety — N/A

Celldex Therapeutics compared to its peers and competitors Companies in this category manage its product and safety risks.
Employee Ownership, Satisfaction, Benefits & Pay — N/A

Celldex Therapeutics among its peers for employee satisfaction and pay. A company’s score on this issue depends on its frequency and likelihood of labor disputes as well as its practices to keep and retain talent - such as compensation, family leave, employee health care and other benefits. Employers that are rated as good to work for consistently produce higher stock returns than their peers.
Workplace Health and Safety — N/A

Celldex Therapeutics among its competitors on this issue. A company’s workplace health and safety is evaluated not only by the number of accidents and injuries in the workplace, but also by their safety policies, training procedures, and their investment in equipment that can reduce accidents.
Integrity of Corporate Governance — N/A

Celldex Therapeutics among its competitors on corporate governance. This score is determined by the company’s accounting practices, executive pay, board organization and ownership structure.
Ethical Practices — N/A

Celldex Therapeutics compared to its peers and competitors. A company’s rating on this issue is based on its history of controversies related to unethical corporate behavior, such as false claims about their products, price fixing, executive misconduct, insider trading or fraudulent practices.
Usage of Conflict Materials — N/A

Celldex Therapeutics among its competitors in this category. Certain products use raw materials that are commonly sourced from militias or other organizations that promote or engage in conflict in their region. To perform well in this category companies must provide adequate assurances that any of these metals used in their production are in fact from conflict-free sources.
Forced Labor — N/A

Celldex Therapeutics compared to its competitors on forced labor. A company’s score on this issue depends on its use of forced labor and on its work conditions for outsourced labor.
Diversity of Corporate Leadership 2 N/A

Celldex Therapeutics performs poorly based on its peers as well as companies in similar geographic regions. Companies are assessed on factors such as board diversity and senior management diversity. Companies performing well on this issue typically are more profitable than its peers, while companies with very poor scores typically have greater stock price volatility and lower returns on capital.

Celldex Therapeutics - Competitors and Related Companies

How Celldex Therapeutics stacks up to its peers in the Biotechnology industry or with competing business segments.